Ann: Foundation Fighting Blindness Presentation Materials, page-10

I suppose we all want the price to keep going up each week and many think that there must be a deal on the horizon for RP11. But put yourself in the position of the possible suitors. I would want to see, as was pointed out in the "fighting blindness " presentation

Transition to therapeutically relevant repeat doses (subsequent data shown will reflect patients treated with multiple 30 or 75 µg doses)

and on top of that i would want to wait and see how things go with the FDA re the agreements on the endpoints for the registrational trial. Whilst all this is happening along with the APKD trial it is a bit of a waiting game, a bit like watching paint dry. We might get a better insight as to how things are progressing next Friday at Q2 investor webinar. Ive certainly got my questions ready

I also personally think that the long game is the technology behind all of the drug candidates, and that type of suitor is not a company thats is looking specifically for ophthalmology drugs or a company wanting a possible cure for APKD, If there is indeed anyone looking at the technology and how it can be used for many other forms of monogenic disorders then that type of deal, which of course may never happen, would make any RP11 deal look like lunch money .... We can only dream

And remember we have time on our side with over $200M in the bank